The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates

International Journal of Infectious Diseases

Volumn 17, Issue 8, 2013, Pages

  Lee, Jina ^a,b   Oh, Chi Eun ^c,d   Choi, Eun Hwa ^c,e   Lee, Hoan Jong ^c,e  

^a Seoul National University Bundang Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University Children's Hospital   (South Korea)

^d Kosin University College of Medicine   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

Author keywords

AmpC; Antibiotic consumption; ESBL; Korean children; Resistance

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE TEM 1; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; KOREA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SEROPREVALENCE;

EID: 84891371575     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.01.030     Document Type: Article

References (25)

1. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Fishman NO, Bilker WB, et al. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis 2005;40:1317-24.
2. Duncan RA. Controlling use of antimicrobial agents. Infect Control Hosp Epidemiol 1997;18:260-6.
3. Jarvis WR. Preventing the emergence of multidrug-resistant microorganisms through antimicrobial use controls: the complexity of the problem. Infect Control Hosp Epidemiol 1996;17:490-5.
4. Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, et al. Control of extendedspectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother 2007;60:629-37.
5. Belaaouaj A, Lapoumeroulie C, Caniça MM, Vedel G, Névot P, Krishnamoorthy R, et al. Nucleotide sequences of the genes coding for the TEM-like beta-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). FEMS Microbiol Lett 1994;120:75-80.
6. Chaibi EB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999;43:447-58.
7. Robin F, Delmas J, Archambaud M, Schweitzer C, Chanal C, Bonnet R. CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum betalactamase detection. Antimicrob Agents Chemother 2006;50:2403-8.
8. Fiett J, Palucha A, Miaczyńska B, Stankiewicz M, Przondo-Mordarska H, Hryniewicz W, et al. A novel complex mutant beta-lactamase, TEM-68, identified in a Klebsiella pneumoniae isolate from an outbreak of extended-spectrum beta-lactamase-producing klebsiellae. Antimicrob Agents Chemother 2000;44:1499-505.
9. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother 2002;46:1-11.
10. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Document M100-S21. Wayne, PA: CLSI; 2011.
11. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46:1481-91.
12. Kim J, Lim YM, Jeong YS, Seol SY. Occurrence of CTX-M-3, CTX-M-15, CTX-M-14, and CTX-M-9 extended-spectrum beta-lactamases in Enterobacteriaceae clinical isolates in Korea. Antimicrob Agents Chemother 2005;49:1572-5.
13. Park YJ, Yu JK, Lee S, Oh EJ, Woo GJ. Prevalence and diversity of qnr alleles in AmpC-producing Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Serratia marcescens: a multicentre study from Korea. J Antimicrob Chemother 2007;60:868-71.
14. Mabilat C, Goussard S, SougakoffW, Spencer RC, Courvalin P. Direct sequencing of the amplified structural gene and promoter for the extended-broad-spectrum beta-lactamase TEM-9 (RHH-1) of Klebsiella pneumoniae. Plasmid 1990;23:27-34.
15. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000;21:455-8.
16. Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook: including neonatal dosing, drug administration, and extemporaneous preparations, 15th ed., Hudson, Ohio: Lexi Comp, Inc.; 2008.
17. Robin F, Delmas J, Schweitzer C, Tournilhac O, Lesens O, Chanal C, et al. Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrob Agents Chemother 2007;51:1304-9.
18. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005;352:380-91.
19. Canton R, Morosini MI, de la Maza OM, de la Pedrosa EG. IRT and CMT betalactamases and inhibitor resistance. Clin Microbiol Infect 2008;14(Suppl 1):53-62.
20. Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002;40:2153-62.
21. Reguera JA, Baquero F, Perez-Diaz JC, Martinez JL. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli. J Antimicrob Chemother 1991;27:569-75.
22. Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 1995;39:2478-83.
23. Wu PJ, Shannon K, Phillips I. Mechanisms of hyperproduction of TEM-1 betalactamase by clinical isolates of Escherichia coli. J Antimicrob Chemother 1995;36:927-39.
24. Miro E, del Cuerpo M, Navarro F, Sabate M, Mirelis B, Prats G. Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction. J Antimicrob Chemother 1998;42:535-8.
25. Robin F, Krebs M, Delmas J, Gibold L, Mirande C, Bonnet R. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM-and complex mutant TEM-producing clinical strains of Escherichia coli. J Antimicrob Chemother 2011;66:1052-6.